Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(19):1493-1494; doi:10.1093/jnci/93.19.1493
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Benson, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benson, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 19, 1493-1494, October 3, 2001
© 2001 Oxford University Press

CORRESPONDENCE

Re: Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial

John R. Benson

Correspondence to: John R. Benson, M.A., D.M., Cambridge Breast Unit, Addenbrooke's Hospital (Box 97), Cambridge CB2 2QQ, U.K. (e-mail: John.benson@addenbrookes.nhs.uk).

The ongoing dilemma over the optimal duration of tamoxifen both in adjuvant and chemopreventive settings is perhaps an inevitable consequence of its identity as a cytostatic rather than a cytotoxic agent (1). Although early in vitro studies revealed tumoricidal effects of tamoxifen, subsequent in vivo data confirmed that short-term tamoxifen acted as a tumoristatic agent and . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?